VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2020 | Treatment optimization trials in breast cancer

Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, discusses optimization of therapies in breast cancer, including the development of escalation and de-escalation studies in order to minimize toxicity and improve efficacy in patients with breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).


Dr. Tolaney has served in a consulting or advisory role for AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Cyclacel, Sanofi, Celldex, Odonate, Seattle Genetics, Daiichi Sankyo, Silverback Therapeutics, G1 Therapeutics, Abbvie, Athenex, OncoPep, Kyowa Kirin Pharmaceuticals, Samsung Bioepsis Inc., CytomX, Gilead, Certara, Mersana Therapeutics.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter